In short
Podcast Summary: "Fast Money" – Big Tech Sells Off.. And Viking Therapeutics Plunges On Weight Loss Pill Data (8/19/25)
Episode Overview In this episode of CNBC's "Fast Money," hosted by Courtney Reagan, the panel of traders discusses significant market movements, including a sell-off in major tech stocks, disappointing data from Viking Therapeutics regarding its weight loss pill, and insights into the housing market.
Key Topics Discussed
- Big Tech Sell-Off
- Magnitude of Decline: Every member of the Magnificent Seven (major tech companies) experienced a downturn, causing a 1.5% drop in the Nasdaq.
- NVIDIA's Performance: NVIDIA reported its worst day since April due to news of developing a more powerful chip for the Chinese market.
- Impact on Other Stocks: Other tech stocks, particularly those associated with AI and crypto, faced declines. Stocks like Palantir and G.E. Vernova saw significant pressure.
- Market Sentiment and Analysis
- Analysis of the Sell-Off:
- Tim Seymour suggested that the sell-off felt like a rotation rather than a panic, citing a lack of significant headlines beyond NVIDIA.
- Karen Beinerman echoed this sentiment, highlighting that while the market has seen extraordinary runs, it’s normal to see pullbacks.
- Dan Nathan analyzed the valuation of stocks like Palantir, noting the disconnect between stock prices and company performance.
- Crypto Market Dynamics
- Guy Adami mentioned that crypto is often a reflection of risk-on/risk-off sentiment in the equities market, with Bitcoin and Ethereum also experiencing declines.
- Viking Therapeutics' Disappointing Data
- Stock Collapse: Viking shares plummeted 42% after revealing unfavorable results from a trial of its obesity pill.
- Patient Discontinuation Rates: High rates of side effects led to significant discontinuation among trial participants, raising concerns about the pill's viability in the market.
- Future Prospects: Analysts debated the company's future, with some suggesting that Viking might remain in the game due to the investment already made, while others questioned its attractiveness for potential mergers or acquisitions.
- Housing Market Insights
- Toll Brothers Earnings: Despite beating earnings estimates, Toll Brothers' stock fell due to lower-than-expected new orders.
- Market Challenges: Experts discussed affordability issues and market uncertainties affecting the housing sector.
- Consumer Behavior: There were mixed signals about consumer confidence and spending in home improvement, with builders experiencing rising costs.
- Intel's Investment by SoftBank
- Market Reaction: Intel's stock rose after SoftBank announced a $2 billion investment, highlighting confidence in the chipmaker's future.
- Government Involvement: Discussions included the U.S. government potentially acquiring a stake in Intel through Chips Act funding, which could impact shareholder interests.
- Media Merger Announcement
- Nexstar Acquisition of Tegna: Nexstar Media Group announced it would acquire Tegna for $3.5 billion, enhancing its reach to 80% of U.S. households. The merger raises questions about the future of local news broadcasting.
Key Takeaways
- Market Volatility: High-performing tech stocks can experience significant pullbacks, signaling a potential market correction or rotation.
- Investor Sentiment: A lack of clear news can lead to heightened volatility; traders should remain cautious and consider valuations.
- Healthcare Investment Risks: Biotech investments can be risky, especially when trial data is disappointing; market expectations can shift rapidly.
- Housing Market Outlook: Although there is some optimism in the housing sector, affordability and economic pressures could hinder growth.
Conclusion The discussions in this episode reflect the complexities and rapid changes in the current market landscape, emphasizing the importance of staying informed and adaptable as new data and trends emerge. The focus on major industries, from tech to healthcare and housing, illustrates the interconnectedness of market factors and the varying investor responses to economic indicators.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq Market site in the heart of New York City's Times Square. This is Fast money. Here's what's on tap tonight. A high flyer flop from big tech to the AI leaders to crypto, some of the year's biggest outperformers coming back down to earth today. What the sell-off tells us about how to play the moves and a strong foundation. Builders bucking the broad market fade as housing starts surge and mortgage rates pullback. Is the group in for more good times ahead? We'll debate it. Plus, heavy losses for Viking therapeutics as its weight loss pill disappoints inside a big investment into Intel and a broadcaster buyout.
0:37So many things to talk about. Let's dive into Nexstar's acquisition of Tegna later on. But first, I am Courtney Reagan, and this evening for Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, we have Tim Seymour, Karen Beinerman, Dan Nathan, and Guy Adami. Let's start off with big tech's sell-off. Every member of the so-called Magnificent Seven down today, not so magnificent, dragging the Nasdaq lower by a percent and a half. NVIDIA, the biggest loser, seeing its worst day since April on reports, it's building a chip even more powerful than the H20 for the Chinese market.
1:10Other chip makers like Marvell, AMD, Taiwan Semi and Broadcom also feeling the heat. And it wasn't just mega caps and chips. Anything tied to the AI trade was also under pressure, including Palantir and G.E. Vernova, the two best performing stocks in the S &P year to date. Also getting hit, crypto, then everything related to it, Bitcoin, Ethereum, both sinking from records. Tom Lee's BitMine down nearly 10 % for its fifth straight day of losses and strategy at its worst level since April. So what does today's action tell you about the durability of the momentum and tech trade? I mean, Tim, it seems like maybe just a rotation today was not terribly heavy on the headlines, other than what we told you a little bit there about NVIDIA.
1:53What do you make of the tech sell-off? Well, the durability of it outside of a couple real spikes in volatility moments over the last year has been that it's not only durable, but it's extremely durable. And I think it will continue to be the place where you're going to get the most growth. Today's trade, though, did feel a little bit like rotation. It did feel a little bit like high flowers were under the most pressure. It did feel like high multiple tech. I have screens that I've actually go through that are high multiple tech companies. A lot of them were down 5 % to 7%. And then you look at the staples, you look at the health care, you look at the home builders.
2:28We're going to talk about places that should be somewhat defensive. Interesting, though, some of the interest rate sensitivity that home builders seemingly have, they definitely have, except for the fact that today was also a day, and I think this has something to do with the risk off, that global bond yields closed again near the highs, if not at the highs. You saw JGB yields. You saw Gilt yields. You saw Bund yields. And while U.S. Treasury yields aren't challenging their highs, Everybody else is. And these are places where they've cut rates. And yet the long end of the curve is going higher.
2:56I think the market has some focus on that, although that's not most investors. I just think we've had an incredible run. And it does make some sense. We're in a very quiet time of the year. Frankly, if you're not on vacation this week, you might be next week if you're lucky. And that's what I think has to do with some of these outsized moves. Interesting. Karen, you're nodding along. You agree? Yes, I agree. Just about everything Tim said. I think that the run has been so extraordinary, right? If you step back a little and just squint at these charts, they're still really, you know, up and to the right.
3:28And I think so there was no particular news that really made anything move. And it's interesting. They all sort of moved together. And you talked about the crypto ones. I mean, even though if you look at something like bullish, you know, that I think did open it. I don't know, 100 percent higher than here, maybe. Right. So that froth seems to be off of a lot of things. And there's still froth to grow, right? But I am long MAG7 stuff. I'm staying long MAG7 stuff. I do still believe in the promise and the growth of AI. I don't think the stocks will move in a linear fashion with the underlying, right?
4:03And I do think that they will peak before the demand peaks. But I don't think that we're there yet. Dan, what about Palantir being in correction? Well, so what's interesting about Palantir, when you're trying to find some reasons why these stocks might have sold off, Citron Research, which is a short seller, they put a note out today saying it's maybe worth 40 bucks. And so when you think about it right here, it was down nine and a half percent. I mean, that's a huge move. And granted, I don't think that report has that much weight other than the fact that sometimes people just need to hear a little bit about this sort of, you know, I mean, listen, it is a bubble.
4:37Make no mistake about it. This is one of the most egregious stocks I think any of us on the desk have ever seen from the disconnection between the company, their products, their management. And this is not on the company. This is on investors. They are the ones bidding this stock up to 100 times sales, to 220 times earnings. And when you trade at a level like that, there's no margin for error, right? And so there's companies are expected to see a deceleration in earnings and sales from maybe 50 percent growth this year to maybe 30 percent next. But this is coming off a very low base. And you kind of think to yourself, OK, what do they have to do to grow into this?
5:15So, again, if you're an investor in this sort of stuff, like you got to understand there's different ways to play this. I think the way Karen's talking about it, these hyperscalers, the investments they are making right now, they will pay off at some point in the future. Right. There's no doubt about that. Maybe not to the tune of the hundreds of billions of dollars in the near term, but five, 10 years down the road to have this sort of infrastructure. That's not what Palantir does. They have a software and it's not even their whole business that has an AI platform that is helping companies move to that sort of technology.
5:46So to me, I don't find that particularly interesting. I do think it's interesting other than the piece of news that we talked about, the short report. There's not a lot out there to do this today. Guy, can you explain to me what's happening in crypto? So I look at that. Some days it's like fundamental. Some days I don't think it is. You're laughing, but explain it. You should say, Guy, can you tell me what the winning lottery number is going to be? Yeah, I'm ready. Tell me. You should get an equally cogent answer. No, I mean, I'm not being flippant. I'm serious. I don't think you are. I think Bitcoin to me or crypto generally is a risk on, risk off.
6:17And as we've seen some pressure in specifically NASDAQ names, I think it's part and parcel what's going on with Bitcoin. So it doesn't surprise me. Why is it happening? I'm not entirely sure, but it's funny. I mean, Bitcoin just made an all-time high of 123. Where's the trade? 112 or something. People are jumping out. I shouldn't say that. They're not cataclysmic in their views, but they're like, why isn't Bitcoin going higher? I think people have been conditioned to believe it's just lower left, upper right. I mean, this is just sort of a normal move for U.S. equities. With all that said, getting back to a couple things, Tim brought up global rates.
6:48He's spot on. For all you people here clamoring for a rate cut, cautionary tale coming out of the Bank of England. I think it's their fourth or fifth rate cut since last August. 200 basis points they've cut. And think about what's been going on with their yields. So if you think somehow cutting yields is going to magically help things on the longer end of the curve, think again, number one. Palantir, by the way, made an all-time high in February at 126. Stock went down 50 percent by April. So it's not like we haven't seen moves like this before. You mentioned correction, and technically that's the right term.
7:17But this is a stock that could easily go down 35 or 40 percent on the back of nothing other than the fact that people might be starting to laser in on valuations. Dan said it takes nothing away with a company that is operating at an extraordinarily high level. It has everything to do with valuations that historically don't make any sense whatsoever. We haven't gotten to NVIDIA yet, but we're going to now because the chart master says the technicals tell him it's actually time to sell this name. So let's bring in Carter Bruxton, worth of worth charting. Carter, what do you see here with NVIDIA?
7:46Yeah, I mean, the weakness today before we get to the charts was not idiosyncratic to NVIDIA. It was a lot of high-flying, marquee, super cap technology-type names. But NVIDIA is the big one, and you have a slight break in trend. Let's go to the charts and see what we can see. I have four in total. The first, as always, has no lines, no drawings, no judgments. Let's put some lines in. So second iteration, you have a well-defined trend line. This is an instance where, of course, the stock has gone from an April low of 87 to 184, about 115 percent. And just today, we broke trend, that very steep uptrend.
8:26Next, third chart of four, it depicts the former highs from which the stock sold off during the tariff swoon and back to which it recovered and then some. So the question is, do we sink all the way down to that level of support? Let's put them all together, four of four. And so we have nothing down, what, four plus minus percent. As Karen said, you'd have to squint your eyes to even see it. But the presumption is that it's not going to be contained to just this one day. And so for those who are nimble and those who do sell short, I would sell short. And for those who are long, it's time to hedge and or reduce in some way exposure.
9:09exposure to this name that we all pay so much attention to. Tim, what do you think of that? Well, I'm always listening to Carter. First of all, the move we've had is has been extraordinary. I look at relative strength as does Carter. Carter probably looks at a lot more than I do. But I see weakness in the Nasdaq relative to the S &P. I see weakness in the semis relative to the Nasdaq. And those are things I follow. I don't know that you're going to see a major reverse course. In fact, they both semis have not. But the Nasdaq made a relative high against the Nasdaq, which it had against the S &P, which it hadn't done since July of last year recently.
9:42That was very strong in confirmation. But I think things are a little hot here. And when you also bring in the context, I know that both NVIDIA and AMD were ready to welcome a 15 percent export licensing fee or export fee to do business in China. I do think there's a lot of there's some uncertainty right now about where the macro is on some of those regular call to regulatory environment call really the where the administration is leading that. I think you have a place here where you've got NVIDIA earnings coming up also on the 27th. And that's a really important event, obviously, for markets.
10:21But for a stock that's had a big run, my guess is there are people that are squaring up going into that. There's so many sort of hot words around NVIDIA when you're talking about the earnings coming up, but also new AI chip. China. Put it all together for us, Dan. Well, here's the thing. I think investors are going to be most focused on margins, right? So when you think about this newly, you know, chip that they're going to be able to export, they weren't able to export the last quarter. They took a five and a half billion dollar charge. Now you're going to suspect that there's going to be lots of demand.
10:46There's going to be double, tripling ordering. And Tim just used the term uncertainty. We don't know how long they're going to have these export licenses. So when I think about this stock, I say to myself, OK, like, you know, it's probably as good as it gets in the near term. I've said that before. But what's different now is that this is 15 percent of their overall revenue that they're going to be giving 15 percent to the government right now that's coming at a much lower margin. When you're taking 15 percent off the top and you're giving it to somebody else, you're going to see their margins that were 77 percent or so last year, maybe go to 70.
11:18And the street is still expecting them to be like 73, 74 to reaccelerate next year. So it may be a very different story. Ultimately, you will get to a digestion phase. There will be less demand. There will be more competition at some point. That's why AMD round tripped almost that entire move. Investors are expecting that. So to me, I think it's a tough one. You look at that chart and you say to yourself, yeah, you squint. But at some point, this is also a stock that sold off 40 % from its highs in March to its lows in April. So it could do it again. Watch those margins. Russell 2000, the market cap is roughly$3 trillion.
11:51NVIDIA is$1.5 trillion more than the entirety of small caps. Good for them, number one. But number two, margins are the story. And, you know, it's historically margins do contract. You do reach a point where competition starts to come in. You start to get peak margins. It starts to roll. Historically, when that happens, is it time to exit these names? We saw glimpses of it a quarter or so ago. They promised a reacceleration in the back half of this year. We're approaching the back half of this year. That's when we're going to hear if it's going to come to fruition or if things are slowing down.
12:21The entire thing, in my opinion, hinges on that. Carter, thank you very much for bringing us those charts on NVIDIA, kicking off that conversation. But we are going to move on to an earnings alert on Toll Brothers, shares of a luxury home builder under pressure, despite beating revenue and earnings estimates for its latest quarter. Our Diane Olek has more of those details. Hi, Diana. Hey, Court, you're right. A beat on the top and bottom lines in Q3 for Toll Brothers. But shares are trading slightly lower because new orders were lighter than expected, down 4%. Guidance was updated to the lower end of the range.
12:52In addition, both the value and volume of units in backlog dropped. That points to maybe some challenges ahead for sales. Now, Toll's CEO, Doug Yearly, said while affordability pressures and uncertain economic conditions persist, we are pleased with the resilience of our luxury business and more affluent customer base. Toll reported home building adjusted gross margin of 27.5 percent versus estimates of 27.3 and unchanged from the previous quarter. The average price on deliveries was$974 ,000, a bit lower than estimates, but the average price on new contracts was$1 million. And remember, about a quarter of toll buyers, Courtney, they do it in cash.
13:33Diana, it's Karen. Thanks for being on. Did they talk about tariffs and what was their take on tariffs? Well, we don't have the call yet. That's tomorrow morning. So this was just the straight earnings release. There was not much in there, nothing at all about tariffs so far. Tomorrow. All right. We will get more and a million dollars for that. Wow. Those are some eye-popping numbers. Diana, thank you so much. We know that you'll follow those color commentary when we get more of the results from the call and executive commentary. Tim, what do you think about the home builder space? Is this a place you want to be?
14:04You were talking about rates earlier on, but rates in general. Well, you know, we had housing numbers today, which were great, all relative to the month before. But generally, you know, new home starts are trending lower. And I don't love the space. I haven't loved the space for the last 18 months. And in there, There's been some nice rallies. But, you know, my general view is that there is a margin dynamic where the builders are eating significantly into the higher rate environment. I think there's a rising cost base that's coming from a lot of different fronts. I think there's a consumer that's under some pressure and affordability.
14:38So the luxury part looks pretty solid and the builders have had a very nice rally. So in the short run, that's my biggest issue here. I think there's no bargain here. There's no beleaguered oversold trade. In fact, I think it's kind of the opposite. I just want to talk about Home Depot for a second. So they had their announcement, you know, the quarterly earnings, which were fine. Right. It was, you know, some pluses, some minuses. And then I think the guidance was, I think, helpful in that it was conservative. But they said this does not include any improvement in any in home improvement. Right.
15:14And so to me, I thought they were being conservative that they actually think there is more there, that we are going to see more home improvement projects. And that seemed like as the quarter went on, things got better. Better. Yeah. So I thought that was really interesting. We'll see Lowe's tomorrow, a little different mix. Home Depot is much more of a contractor business. And but I thought that was pretty positive. Yeah, I mean, when I talked to the CFO, I said, well, what would get homeowners to get off of sort of the waiting period where he said, well, the projects aren't canceled. They're just delayed.
15:47They're just deferred. I said, well, what gets them over the edge? Well, we don't know. I mean, it's economic uncertainty. But if they do push that over the edge, it does help. And Home Depot's pro business, I think, is 55 percent. How does the CFO know that? I mean, like to me, we're in an environment where, you know, we're seeing unemployment tick up. We're seeing inflation tick up. We're seeing a consumer weakening delinquency is going higher. I mean, it just seems like an odd thing for them to say we're seeing smaller renovation stuff, but we're seeing a push out and that sort of thing. So to me, I just I looked at the quarter.
16:15I looked at the current quarter, like the way the commentary I look at the back half or what their willingness to kind of endorse, you know what I mean, their existing guidance. And I said to myself, there's more uncertainty there than there is clarity. Yeah, I thought it was very interesting that they actually reaffirmed that. I thought it was more conservatism. Well, it could be. But I mean, but that's a big assumption, too. I don't think you have to make an assumption that things are going to get pushed out right now when you look at just, you know, the environment that we're in right now. When you look at interest rates and you look at what's going on in some of the other commentary we've heard from the home builders, you know.
16:45So I don't know. I mean, I didn't think it was particularly great. And I look at a lot of the retailers. None of them, none of them have confirmed the highs in the S &P 500. And we had plenty of them in June and July, basically new highs in the index. Yeah, that is true. We're going to hear from a lot more of those retailers coming forward. Lows, as Karen mentioned, tomorrow, but others as well. And as we mentioned, I think it was Tim, housing starts to come in better than expected in July. But Zillow's senior economist isn't betting on new construction rebound just yet. Orfei Devongue is behind the call.
17:13He joins us now. Thank you so much for being here with us. I understand you look at this, of course, from an economic viewpoint rather than a stock perspective. But when you're looking at the housing market in general, what are you seeing? Are you seeing homeowners really waiting because they're hoping that rates pull down in a way that gets them to move? off the reluctance that they've felt so far? Look, affordability is still the main issue in housing today, you know, across the board. We're seeing affordability improving somewhat, you know, in places where builders have built a lot of housing.
17:49But this is still a problem. And so in places where you see a big increase in inventory, you're seeing a builder pullback. You know, you saw the numbers this morning. Permits are lower than, you know, fell for the first half of this year. They're lower than they were a year ago. And so that doesn't point to a lot of supply in the months ahead. Orfei, I think the average number of homes in terms of inventory, new homes in this country, about six, a little less than six months. As of June, I think it's up almost to 10 months, the highest number we've seen since 2008. Now you're hearing the home builders average selling prices have been coming down.
18:25I mean, that doesn't sound as much as people want to talk about this robust housing market. It sounds like anything but to me. Thoughts on that? Yeah. Let me start with the bad news since you since you went there. Look, uncertainty, I think, is is the problem. Right. It caused private sector job growth to reach what we call stall speed. People don't go out buying a new house when they're not getting a raise in inflation, eating at their paycheck. You know, they don't buy a house or a new car when they're kind of uncertain about their job prospects. And so that frozen labor market hasn't helped residential mobility.
19:01We know from the data that the number one reason people move is first and foremost a job. We're seeing that softness also play out in the rental market. Now, here's the good news. Mortgage rates have been on the decline since May. And historically, we know the Fed has put more weight on the labor market side of the mandate. And so we may see some support. I think ultimately a strong economy is how we see more activity in that in the housing market. Orphets, Tim. So let me go a little deeper on that and really play into your economist hat. So rates could be coming lower. We've just talked about how rates are going higher.
19:38Talk about history and where the housing market has been at a time when rates aren't terribly low relative to their recent history. Even if the short end is dropping, we know that doesn't mean mortgage rates get better. Just just thoughts on the industry relative to this type of an interest rate environment. Yeah. Look, ultimately, the changes in interest rates are in mortgage rates matter. But other things matter, too. Right. And so, you know, ultimately, the Fed rate cut is not really what's going to move the needle, I think, for mortgage rates. they're somewhat already baked in to today's rate.
20:13So I don't expect mortgage rates to decline very much. I think what has hindered the housing market this year is really the dwindling labor market prospects, the uncertainty that we saw in the spring. And this is kind of slowly resolving itself. And I think rate cuts are going to kind of help. Hopefully, we had that labor market report that kind of just confirmed, you know, one thing I had been talking about for months, even before the double revisions, was the slowing down of the labor market, right? And that showed up big time in the housing market this year. Mortgage rates, I think people are getting accustomed to the current level of mortgage rates.
20:57If you look at the behavior of sellers, sellers are basically back to kind of their typical behavior. They came back in the spring and now we're starting to see a decline in new listings on Zillow. And so that decline in new listings coupled with the pullback from builders is going to provide some support for prices for home values. And unfortunately, it means that buyers in this current moment who have more options than they've had in a long time and more price cuts than they've had in a long time, well, that might not stick around very long. If you start to see a pullback in supply, last month we had 27 percent of listings on Zillow had a price cut.
21:36Right. If you start to see a pullback in supply, that those conditions, that softness could get could get away from them. Orfe, thank you so much for joining us with your perspective. Appreciate that ahead of Jerome Powell's speech, obviously, this week, which sort of sets the bar for everything at which rates are based on. Karen, you talked a little bit about cost when you were asking Diana about Toll Brothers and what they had to say with tariffs. Any play in like materials going into home building? We talked about Home Depot, the retailer, but what about the materials at which you're building these homes with?
22:08Well, that's why I go to Home Depot scale. Right. When I think about if there's anyone who can deal with the tariffs, it's like it's a Walmart. It's a Home Depot who has the ability to maybe get some of it out of where they're importing from, be a little bit more efficient and take a little bit of price. So that's where I want to be. OK, makes sense. Well, coming up, another boost for Intel. SoftBank giving it a big vote of confidence what the investment means for the stock. And could the U.S. government be the next to follow suit? Plus, a crash diet for shares of Viking therapeutics. The disappointing obesity pill data is sinking that stock.
Read the full transcript
22:46And what it could mean for its prospects as a takeover target. Don't go anywhere. Fast Money back in two.
22:57Welcome back to Fast Money. Intel getting back into rally mode, charging 7 % higher after Stock Bank announced a$2 billion investment in the chipmaker. The stock is now up seven of the last eight days and down at the last 12. Christina Parts and Evelis is joining us on set with more. Christina, Parts of Knowledge. Oh, that's a good one. Oh, I thought you said Parts of Knowledge. Oh, I like that, too. What's my last name? I think we've got something to do. I've never heard that one. I've heard Parts of Knowledge or Leave Us, Parts, an elephant. Okay, but I have a long last name. But what we need to know about Intel is that it got a vote of confidence today from the SoftBank investment.
23:32Last night, I reached out to Intel to find out just in regards to how many shares, all that. They did say it was going to be a primary issuance, which means new shares. Therefore, you know, SoftBank taking a 2 % would dilute. But you saw the stock actually climb higher. Why? Because SoftBank also has investments in OpenAI and Arm. Arm, we know, is working on creating a new chip. This could be a nice little way for SoftBank to funnel that foundry business or chip manufacturing business to Intel. So that's part one. The other part of the story is the White House today. The Commerce Secretary, Mutnick, was on CNBC at 10 a.m.
24:06and did confirm that they do plan to use the Chips Act funding, or they're looking at it, Chips Act funding to buy a 10 percent stake in Intel. They were very specific to say no voting rights. They don't care about that. They just want an equity stake, which is great for the government because previously it was taxpayer dollars just being a handout to Intel. Bad for Intel because now they're not really getting as great of a deal. They get the money, but then they have to give equity away. And so the concern from some people is that it's not always going to work in the shareholders' best interest.
24:36Why do I say that? Because they're so focused on the foundry business. They're so focused on the foundry business. Maybe the foundry business shouldn't survive. Maybe it's not as valuable. It's been struggling and won't turn a corner until 2027. But the government doesn't want that. But they weren't going to get those milestones. They weren't meeting those milestones anyway that I thought were necessary to get the rest of the money. There was a long time delay. Yes. Yes. So there's a long time. So that's a good point. That is a very good point that, you know, they had factored in this money. Well, maybe Intel had factored in this money for that long time frame anyways.
25:09And we just didn't know how behind they were. So to your point, yes, you know, it wasn't going to play a big role right now. guy. We're lucky to have her doing this space. Christina has immersed herself in the semiconductors. I know. She really is. My question to you is like an SAT question. Taiwan Semi is to Taiwan as Intel is to the United States. And I think that's sort of the lens that this administration wants to look. It's a security. But she would have called it false if she was taking the SAT. I'm sure she crushed it. She would have said false. Yeah. So I just said, hmm. Or D, none of the above.
25:39Yes. But I do think that is a possibility. And I don't think that's the goal, though, not necessarily a possibility just now. Well, that's a goal. From the government. But what I'm saying is, I don't think their business is fixed, but I think the stock in the short term could be fixed, and that's what we're trying to focus on. Well, what kind of value is that if it's just momentum traders getting in, and you're not really talking about the fundamentals of the business that's not going to change because of the manufacturing process? You have people just rushing into the stock for headlines, let it fade after a little while when they realize how long it's going to take for this to trickle on in.
26:08I want to ask you about the industry validation that comes from SoftBank for dumping$2 billion in here. When SoftBank has thrown so much money around to be close to this administration, and this to me just seems a small vig for them. By the way, SoftBank, who does, I mean, yeah, I understand they have some incredible investments over the years, but they've also got a fair amount of egg on their faces as well. So if you're rallying this on a$2 billion SoftBank investment, I'm leading the witness. What do you think about this? SoftBank is just doing it to say, well, no, I shouldn't say just doing it.
26:41I don't know their team, but it's going to contribute to the$100 billion that they promised. And it, you know, it signals a handshake. It's a nice little handshake with the president, right, and building on American soil, just like they bought the Foxconn EV plant in Ohio. It's about spreading their footprint in America. Because if the nationalist, you know, push by the government continues with even the next president, SoftBank is positioning themselves well. Not only has Christina immersed herself in the chip space, but also as an American. I know, because I'm Canadian. I even got caught by saying Ohio's a swing state, and it's not.
27:14It is. I'm from Ohio. I'll call this. See, I don't know. Like I said that incorrectly. It's all about Ohio, by the way. Everything comes back from Ohio. It's all about Ohio. Everyone's paying attention. Thank you, Christina. There's a lot more Fast Money still to come. Here's what's coming up next. Pillaging Viking. Shares of the biotech hitting stormy seas after its latest trial data. What it had to say about its obesity pill that had investors running scared. Plus, a TV team up. Two broadcast giants coming together in a media merger. What it could mean for competition in the space and for the future of bundling.
27:49You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.
28:02Welcome back to Fast Money, another check on how stocks closed the day. The Nasdaq lower by one and a half percent, the S &P down by half a percent. But the Dow eaked out a small gain, touching a record high earlier in the session. Shares of Best Buy up three percent after the company launched a third-party marketplace in an effort to boost slowing sales. The stock's still down nearly 14 percent this year. And Netflix lower today. Analyst at J.P. Morgan reiterating a neutral rating on the streaming giant. Dan, you flagged the move in Netflix. Yeah, this one that I think is universally loved. Even after that quarter, I know the stock sold off 5 % the next day.
28:37And I guess the only thing that sticks out to me about Netflix here is that, you know, when you think about the content that they're going to buy right now, whether it's sports and, you know, like they're bidding for sports rights. And we know that that's been a really difficult thing for lots of different networks. So they'll probably make it work. But in the near term, when they're not giving subscribers, and I know that was a big driver of the stock, or at least some of the metrics that a lot of investors focused on, they're going to have to get their arms around how much they're actually going to spend.
29:03And listen, the stock's been great. That's on investors. This company has a lot of transparency despite that subscriber number. So to me, I don't think there's any reason to run from it, but I think there's probably easily more downside. All right. And it was down 2.5%. Well, coming up, a biotech burnout. Now the Viking Therapeutics cratering after disappointing obesity pill data. What it means for the weight loss drug race. That's coming up next.
29:35Welcome back to Fast Money. Viking Therapeutics sinking 42 % today for its worst day on record. The company out with its new data on its experimental obesity pill showing a competitive weight loss profile. But high rates of side effects and patient discontinuation. Angelica Peebles joins us with more. Hi, Angelica. Hey, Courtney. Well, that's right. People lost up to 12 percent of their body weight after about three months at the highest dose. But it's unlikely that Viking will actually be able to advance that dose because people couldn't tolerate it. So overall, 28 percent of people stopped taking the drug and 20 percent stopped because of the side effects, mainly nausea.
30:10And the discontinuation rate was even worse at that highest dose. Viking executives on a call earlier today said that it's too early to say exactly which doses they'll ultimately move into phase three. Though they did say that it's possible that they'll use lower doses for maintenance. So once people have lost a significant amount of weight and maintenance, of course, is one area where people think that pills could play a big role. But beyond that, these data were raising more questions about where exactly orals fit into this market and how large that opportunity will be. And those questions are especially important for Viking since the company's going to be years behind Novo and Lilly, who have shots and pills on the market years before Viking even gets there.
30:48Courtney, thank you, Jack. I know you've been following this all day for us for more on Viking and the obesity pill race. Mizzouho health care strategist, Jared Holtz, joins us here on the set. You know, beyond just the patients being nauseous, investors are to today down 42 percent. Is this it? I mean, are they done? Is Viking Therapeutics out of this race for the obesity pill? I don't think they're done. I mean, it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is. But this sort of discontinuation rate, when you have monster companies that are ahead of them, I think that's really the point.
31:20You've got the largest, most well-capitalized pharmaceutical companies that are two to three years ahead. I think that's really why investors sour to the data. So if you were the CEO of Viking, I mean, do you go back to the drawing board on this and figure out the dosage? Or you say, hey, we got to play somewhere else. We're two or three years behind, like you just said. Can they catch up? I think they've invested too much to call it quits at this point. I mean, these biotech companies resurrect themselves time and time again, and sometimes you pull a rabbit out of a hat. Maybe the low dose winds up being tolerable, and therefore it does become a maintenance therapy for people that have already gotten on the shots and have lost weight.
31:54So obviously we talked about the stock price getting hit so hard today. Does this make them look attractive as a target for a takeover? I would doubt it. I mean, you can't, I don't think you can buy the company at this stage of the game unless you are sure that a lower dose oral obesity pill that they put out with what is probably going to be less than 10 percent weight loss is going to be a big product. I just feel like any pharma company that would dare to do this now would get punished for it. So one player off the board, does this strengthen Novo, who's been, we've talked about it with you, you have not been a fan, you have been right.
32:27Does that help them in any way? Well, I think investors are starting to come back to Oral Wegovy because of the profile, especially since the Orphaglipron data from Lilly didn't look as good as we all thought it would. So it's kind of like the competitive setbacks have put Novo in a better light. They've kind of benefited from everyone else. So, yeah, I think Novo looks a little bit better. And so combine that with the news that we've had this week on essentially the DTC through GoodRx and, you know, and maybe this pressures Lilly a little bit on price. So$4.99 is for cash paying customers. Does that change anything?
33:03Do you worry about Lilly in the context of margin because of that? Not really. I mean, the companies have basically both addressed price proactively, right? You see Novo continue to lower price. Lilly has lowered price. They were the first company to go direct with their own offering. And so I think they're essentially both around$500 a month now, give or take. So to me, it doesn't impact Lilly as much. So just going to Novo's oral drug, which actually had greater weight loss, right? But this not being able to eat for 30 minutes, how gigantic or not is that for someone who would be interested in an oral drug versus what Lily has at lower percentage weight loss, but you don't have that?
33:46Right. Not a huge deterrent. I mean, the whole point of the pill is to not eat anyway. so when I look at it I think the biggest issue for Novo is going to be actually making the drug you know a lot of ingredients go into these pills Lily has an easier opportunity from that standpoint the the actual regimen of taking the pill not as a not as big of a factor for me so obviously I'm not a doctor forgive me but try to changing the dosage of the pill does that really matter? I mean, would that make you less nauseous than something like an injection? I mean, how big of a differential is that? Yeah, well, first of all, there seems to be a worse adverse event profile with the pills versus the injectables.
34:29That's what we've seen from all the companies so far. So if patients are looking for what they feel are going to be the best products from a tolerability standpoint, the shots at this stage of the game are better. The orals might just wind up being more maintenance therapy. I think the assumption that a lot of investors have on this Viking data and also with Lilly is if you go down dosage, the efficacy or the weight loss is not as good. So either what's the point or you're going to have to figure some other way to lose weight. Before we let you go, what would be your best trade idea if you want to bet on the weight loss space?
35:05This isn't Shadur and a number one for Micah. Okay. Sorry. I like Lilly on pullbacks. I mean, that's kind of like the trade that I think continues to work. Every time there seems to be a setback there, I still think when you look at their pipeline and the opportunity, plus how well capitalized they are, they can do a variety of things strategically, more M &A in other areas. I think Lilly's the one that you want to buy for a trade on any weakness. All right, go Brownies. Well, sort of. I mean, yeah, look. Team has yet to be the Super Bowl, the Cleveland Browns, the proud franchise Cleveland, your home state of Ohio.
35:45Because everything comes back to Ohio. So far from the cardiac kids with, you know, Saip and Co., that was an exciting team. Yeah, but they never got to the promised land. A lot of people don't. Kevin Mack, if you recall. A lot of people don't. Just don't count out Ohio. One day, you never know. It's all about Ohio. In a Super Bowl. See? Everything comes back to it. Thank you, Jared. Thank you for being here with us. Thank you. Well, coming up, talk about a TV bundle, a media mega merger, making headlines, and what it means for competition in the broadcast network space. That's next. Best Money.
36:12back into it.
36:26Welcome back to Fast Money and Next Star Media, the largest operator of local U.S. TV stations, is set to acquire rival Tegna for$3.5 billion, creating a company that reaches about 80 percent of U.S. households. Next Star will pay$22 per share for Tegna. The deal is expected to close by the second half of next year. Of course, that assumes that it does close. Is this a bid for local news stations? Well, it's interesting because this is obviously a bit of a throwback, right? This is actually almost the reverse into the cable deal, back into the bundle. But it's been a fascinating time. I think what this speaks to is in the media space, we've seen real sum of the parts value investors or value M &A.
37:07And I think this is a case where people looking at the metrics that they one point thought they could no longer. And that's even in a declining cable market and linear TV. This is a deal that seemingly makes some sense. I think there's a lot more deal flow to go in this space. Tim, do you think there's some regulatory issues that might be there? Just if you think about market share, you put these two together. I've heard some wise men talk a little bit about the FCC, and this may be a good environment to get deals done and maybe strike while they aren't hot. Right. Yep. Well, coming up, liquid assets.
37:35That's why restaurants are leaning into beverage options on their menus. Don't go anywhere. Fast Money is back in two.
37:52Welcome back to Fast Money. Restaurants and fast food chains seem to have a new strategy to bring diners in the doors, focusing on adding new beverages to their menu. CNBC's Kate Rogers has more. Kate? Hi, Cord. So if it feels like there are a lot of drinks on store menus right now, it's because there are. Innovations are being unveiled at Starbucks, which is leaning into protein, coffee, cold foams later this quarter. McDonald's, which is launching a beverage test of what it's calling dirty sodas and specialty iced coffees at 500 stores in September. And that is really just the start. Now, according to data from Technomic, the number of beverages offered by top 500 chains has increased 9.2 percent over the past four quarters.
38:30Last year, the primary driver for beverage sales was getting a pick-me-up, the data found, with 22 % saying that was their most common reason for going. That's up from 20 % in 2023. Washing down food as a beverage occasion, that stood at 20%, so the drink alone is increasingly the reason for the purchase. Ice beverages and energy drinks are driving brand interest, and brands are catering toward Gen Z's love of custom cold drinks. We talked to Dutch Bros CEO Christine Barone on how she's evaluating beverage innovation. Take a listen. I think the key with innovation is to really understand when something might be ready to pop or something might be of high interest and then be able to move really fast to execute on it well.
39:14So essentially and increasingly, customers are really driving the conversation. And my takeaway in talking to the Dutch Bros CEO and also the chief marketing officer at Dunkin' was just about the idea that this needs to be a special occasion and something unique and different that you can't really make at home in this very competitive consumer environment. Court, back over to you. It's so interesting. I'm all about this, Kate. I actually spent$10, which is a lot for me, on a protein drink the other day at a grocery store. and I bought it specifically for the protein. So I perked up when you mentioned that part of your report.
39:48Can you tell me more about some of the big chain sort of investing in that area? If you're on Instagram and you're a woman around my age, all you're getting told is you need more protein. Yeah, more sleep, more protein, more hours in the day, right? But Dutch Bros has been ahead of the curve on this. They had launched protein milks in 2024, and their CEO told us that that's been a nice boost for sales for them. And then Starbucks in late Q4, its CEO, Brian Nickel, talked about how they're going to be expanding this test and launching cold foam that has protein in it. You can add essentially 15 grams of protein to any cold beverage.
40:24We know cold beverages are so key. As you mentioned, this protein trend is really spreading and targeting women in particular on social media. So we'll see how that does for their sales. But definitely an interesting trend and, again, a nice way to boost your protein intake in the morning. Hey, I'm following along. I am interested in these innovations. Guy was laughing at dirty soda. No, I'm not. Trust me, I'm not laughing. What do you think? Is this a way to increase market share for some of these players in the restaurant space? Can you give some good data? 9.2 % more beverages? I'm going to bring it right back and say this is an attempt.
40:56Drinks are high-margin businesses. Remember the scene in Pulp Fiction. You're going to wash that tasty burger down with that refreshing drink, and that's what I think these restaurants have tapped into. High margins. Give people what they want. This is a way to combat rising prices and to try to somehow keep your margins going. But I think Tim has some thoughts on high-protein drinks as well. Well, I tell you what, I think there's a lot more protein in the glass of milk you could be pouring at home. So this is, you know, the PSA for the American Milk Society. You know what, that's a great point.
41:26No, seriously, my son was, you know, getting into, like, these protein drinks, and I looked at the back of the milk carton, and this is 26 grams, and the other one's got, like, 28. Big deal. Drink a glass of milk. There you go. I mean, that's the way I can hit that 100 grams. We're supposed to be getting 100 grams of protein. I guess we'll drink more milk. Anyway, Lazy Boy shares dropping after hours, down over 20%. The company just reporting results in midweek guidance. The stock at levels not seen since November 2023. Nobody's sitting at Lazy Boy's. Too busy drinking protein. Anyways, coming up next, your final trades.
42:07It's time for the final trade. Let's go around the horn. Tim, you start. Well, first of all, Courtney, great to have you. It's all about Ohio. I mean, let's get that out there one more time. And in the media space, we talked about it tonight. Disney. I actually like what's going on in the chart. Fundamentals. Long-term investment. Karen. Thank you, Court. Being here. Uber. I like it, but actually at this price now, it's getting this gravitational pull towards$100. So staying long Uber. Dan? Guy had good commentary last night and tonight on Intel. But I wouldn't chase it here. Okay, and Guy. Jason's spinning some great music in the breaks.
42:41A little Shania Twain. We just had some Bon Jovi. And it's always fun when Courtney's here. I think we have Brian Sullivan tomorrow. Tease. Newmont Mining. Thank you for watching Fast Money. It's fun to be here. Mad Money starts right now.
43:23Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash Fast Money disclaimer.
From the publisher
Tech taking it on the chin, as big tech sells off in today’s session. The Mag-7 names pulling down the space, and the semi stocks feeling the heat. Plus A biotech bummer. Shares of Viking Therapeutics tanking after the company posted disappointing weight loss drug pill trial data. What it means for the company’s next move, and the impact it could have on potential M&A action.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
